1 Stock Down 35% This Year You’ll Regret Not Buying on the Dip, According to Wall Street
It’s been a challenging year for NovoCure (NASDAQ: NVCR), an oncology-focused biotech. The stock is down by 35% since early January. Though marketwide issues probably didn’t help, NovoCure mostly has itself to blame for its year-to-date performance. Its shares declined after a disappointing fourth-quarter update. Still, the stock could have significant upside potential. NovoCure’s average…